Skip to main content

Table 1 Demographic characteristics of the patients at baseline

From: Evaluation of the advantages of robotic versus laparoscopic surgery in elderly patients with colorectal cancer

 

Robotic surgery (n = 55)

Laparoscopic surgery (n = 56)

Overall (n = 111)

P

Age, median (IQR), years

82(81–85)

82(81–84)

82(81–85)

0.202

Gender, n (%)

   

0.294

Male

31(56.4)

37(66.1)

68(61.3)

 

Female

24(43.6)

19(33.9)

43(38.7)

 

BMI, mean (SD), kg/m2

23.8(3.6)

23.3(2.7)

23.5(3.2)

0.362

ASA score, n (%)

   

0.782

II

26(47.3)

30(53.6)

56(50.6)

 

III

28(50.9)

25(44.6)

53(47.7)

 

IV

1(1.8)

1(1.8)

2(1.8)

 

Previous abdominal surgery, n (%)

10(18.2)

24(42.9)

34(30.6)

0.005

Hepatobiliary surgery

5(9.1)

6(10.7)

11(9.9)

 

Gynecological surgery

2(3.6)

7(12.5)

9(8.1)

 

Appendectomy

4(7.3)

11(19.6)

15(13.5)

 

Anterior resection

0(0)

1(1.8)

1(0.9)

 

Inguinal herniorrhaphy

0(0)

2(3.6)

2(1.8)

 

Urological surgery

1(1.8)

1(1.8)

2(1.8)

 

Comorbidity, n (%)

44(80.0)

32(57.1)

76(68.5)

0.010

Coronary heart disease

12(21.8)

11(19.6)

23(20.7)

 

Diabetes

12(21.8)

6(10.7)

18(16.2)

 

Cerebrovascular disease

10(18.2)

6(10.7)

16(14.4)

 

Hepatitis

2(3.6)

2(3.6)

4(3.6)

 

Renal disease

4(7.3)

2(3.6)

6(5.4)

 

Hypertension

30(54.5)

27(48.2)

57(51.4)

 

Pulmonary disease

4(7.3)

3(5.4)

7(7.6)

 

Synchronous tumor*, n (%)

4(7.3)

5(8.9)

9(8.1)

 > 0.999

ACCI, mean (SD)

7.1(1.1)

7.2(1.8)

7.2(1.5)

0.505

Neoadjuvant therapy, n (%)

2(3.6)

0(0)

2(1.8)

0.243

Tumor location, n (%)

   

0.391

Ascending colon

16(29.1)

19(33.9)

35(31.5)

 

Transverse colon

0(0)

2(3.6)

2(1.8)

 

Descending colon

2(3.6)

1(1.8)

3(2.7)

 

Sigmoid colon

13(23.6)

16(28.6)

29(26.1)

 

Rectum

22(40.0)

15(26.8)

37(33.3)

 

Other**

2(3.6)

3(5.4)

5(4.5)

 

Serum CEA, median (IQR), μg/L

4.4(2.6–9.9)

7.3(3.3–20.8)

5.5(2.9–13.4)

0.754

Missing data, n (%)

0(0)

1(1.8)

1(0.9)

 

Serum CA19-9, median (IQR), u/mL

14.3(7.8–20.5)

18.9(8.9–42.6)

15.8(8.6–29.4)

0.079

Missing data, n (%)

0(0)

1(1.8)

1(0.9)

 

Serum CA724, median (IQR), u/mL

2.7(1.6–5.2)

2.3(1.4–6.6)

2.6(1.4–5.3)

0.805

Missing data, n (%)

3(5.5)

5(8.9)

8(7.2)

 

Serum CA125, median (IQR), u/mL

11.3(8.0–18.8)

12.4(8.8–16.3)

11.6(8.4–18.1)

0.803

Missing data, n (%)

1(1.8)

3(5.4)

4(3.6)

 
  1. Abbreviation: IQR Interquartile range, BMI Body mass index, SD Standard deviation, ASA American Society of Anesthesiologists, ACCI Age-adjusted Charlson Comorbidity Index, CEA Carcinoembryonic antigen, CA Carbohydrate antigen
  2. *The robotic group has 2 patients with synchronic liver metastasis, 1 patient with synchronic lung metastasis, and 1 with synchronic ovary metastasis. The laparoscopic group has 4 patients with synchronic liver metastasis and 1 with synchronic ovary metastasis
  3. **The robotic group has 1 patient who developed ascending colon tumor and rectal tumor simultaneously at admission, 1 patient who developed ascending colon tumor and sigmoid tumor. The laparoscopic group has 1 patient who developed ascending colon tumor and rectal tumor simultaneously at admission, 1 patient who developed ascending colon tumor and sigmoid tumor, and 1 patient who developed sigmoid tumor and rectal tumor